Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sanofi's (SNY) Enjaymo gets approval to treat hemolytic anemia in adult patients with cold agglutinin disease (CAD) in Europe.

Sanofi's (SNY) Rare Anemia Drug Enjaymo Gets EU Approval

European Commission approves Enjaymo ® ( sutimlimab ) for treatment of hemolytic anemia in adult patients with cold agglutinin disease

Press Release: European Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease

The CHMP recommends approval of Sanofi's (SNY) Dupixent for the treatment of prurigo nodularis, a chronic inflammatory skin disease.

Sanofi (SNY), Regeneron Dupixent Gets CHMP Nod for Skin Disease

Snowflake

Meta's massive layoff announcement led our coverage this week, but on the other end of the spectrum, biotech company Sanofi announced a billion-dollar deal in AI drug discovery.

Sanofi (SNY), GSK Receive EU Approval for COVID-19 Vaccine

Dupixent ® (dupilumab) r ecommended for EU a pproval by the CHMP for the treatment of p rurigo n odularis

Press Release: Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of prurigo nodularis

GlaxoSmithKline

Sanofi and GSK's next-generation COVID-19 booster vaccine Vid P revtyn ® Beta approv ed by the European Commission

Press Release: Sanofi and GSK's next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission

Sanofi said on Thursday it won European Union approval for its COVID-19 vaccine booster, jointly made with British partner GSK , after a drawn-out development effort that saw the pair fall behind now-dominant vaccine suppliers.

Sanofi, GSK score late win with EU COVID booster approval

European Commission grants first approval worldwide of Beyfortus ® (nirsevimab) for prevention of RSV disease in infants

Press Release: European Commission grants first approval worldwide of Beyfortus® (nirsevimab) for prevention of RSV disease in infants

ABB Ltd.

Arbor Realty Trust

Amcor Plc

Franklin Resources

Enterprise Products Partners

Essex Property Trust

eXp World Holdings Inc

Federal Realty Investment Trust

Innovative Industrial Properties

Kinder Morgan

Leggett & Platt

Main Street Capital

Magellan Midstream Partners

Philip Morris

Starwood Property

Stanley Black & Decker

Walgreens

A February 2, 2022, Kiplinger Today special report headlined, "Potent Picks to Profit in 2022,” featured 97 dividend-fetching stocks from 118 in that article per YCharts 10/28/22 data. Article-titles were: "65 Best Dividends"; "15 Value Stocks"; "15 Best Mid-Caps"; "10 European Plays"; "9 High Yields"; and "6 Sturdy Defensive Stocks."

13 Potent Picks Are November's Ideal Dividend Buys

Sanofi SA (NASDAQ:SNY ) Q3 2022 Results Conference Call October 28, 2022 8:30 AM ET Company Participants Eva Schaefer-Jansen - Head, IR Paul Hudson - CEO Bill Sibold - EVP, Specialty Care; President, North America Thomas Triomphe - EVP, Vaccines Olivier Charmeil - EVP, General Medicines Julie Van Ongevalle - EVP, Consumer Healthcare Jean-Baptiste de Chatillon - CFO John Reed - EVP & Global Head, Research & Development Roy Papatheodorou - EVP, General Counsel & Head of Legal, Ethics & Business Brendan O'Callaghan - EVP, Global Industrial Affairs Conference Call Participants Graham Parry - Bank of America Securities Wimal Kapadia - Bernstein Richard Parkes - Exane BPN Emily Field - Barclays Peter Welford - Jefferies David Risinger - SVB Leerink Jo Walton - Credit Suisse Peter Verdult - Citigroup Luisa Hector - Berenberg Richard Vosser - JPMorgan Keyur Parekh - Goldman Sachs Eva Schaefer-Jansen Good morning, good afternoon, and good evening to everyone. Thank you for joining us to review Sanofi's 2022 third quarter results, followed by a Q&A session.

Sanofi SA (SNY) Q3 2022 Earnings Call Transcript

Sanofi (SNY) beats third-quarter estimates for earnings and sales. Dupixent and flu vaccines drive sales growth.

Sanofi (SNY) Q3 Earnings Beat, Dupixent, Flu Jabs Push Sales

Sanofi stock jumped Friday after the company reported better-than-expected third-quarter profit, leading to a guidance boost. The post Sanofi Jumps As Strong Third-Quarter Profit Leads To Guidance Boost appeared first on Investor's Business Daily.

Sanofi Jumps As Strong Third-Quarter Profit Leads To Guidance Boost

The company raised its view on business earnings per share, saying that it expects the metric to grow about 16% at constant exchange rates.

Sanofi posts higher sales but $2.07 billion net profit misses forecasts

VELIZY-VILLACOUBLAY, France--(BUSINESS WIRE)-- #3DEXPERIENCE--Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) and Sanofi today announced their partnership to optimize “EVolutive Facility” production at Sanofi's future state-of-the-art modular manufacturing facilities in France and Singapore.

Dassault Systèmes Partners with Sanofi to Optimize Tech Transfer and Industrialization at Its Future “EVolutive Facilities”

Medical Properties Trust

Zoetis

Two of these three pay especially attractive dividends.

3 Dividend Stocks That Could Soar 51% to 58%, According to Wall Street

Intel

2 High-Yielding Dividend Stocks That Haven't Been This Cheap in Years

Dupixent ® (dupilumab) late-breaking P hase 3 data presented at UEG Week 2022 showed significant histological remission of eosinophilic esophagitis ( EoE ) in children 1 to 11 years o ld

Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data presented at UEG Week 2022 showed significant histological remission of eosinophilic esophagitis (EoE) in children 1 to 11 years old

Bank of America

Airbus SE

General Motors

Unilever

Although crimson seems to be the shade of the moment in the equities sector, by targeting under-$50 stocks to buy, astute and daring investors may be able to tap into a hidden bull market. How can this be?

7 Under-$50 Stocks to Buy to Tap Into a Hidden Bull Market

Provention Bio Inc

Sanofi US to co-promote teplizumab, adding it to its current commercial activities in diabetes care, leveraging its existing best-in-class customer-facing field teams Provention Bio, Inc. retains all rights to teplizumab Commercialization activities are dependent on U.S. FDA approval of teplizumab, potentially on November 17, 2022 BRIDGEWATER, N.J. , Oct. 6, 2022 /PRNewswire/ -- Sanofi US has announced it has entered into a co-promotion service agreement with Provention Bio, Inc., for the commercialization of teplizumab in the United States.

Sanofi US enters into co-promotion agreement with Provention Bio, Inc. to launch teplizumab, an investigational disease-modifying therapy for type 1 diabetes

Dupixent has become the key top-line driver for Sanofi (SNY). Sanofi possesses a leading vaccine portfolio, which has become the primary top-line driver.

Sanofi (SNY) Relies on Dupixent and Vaccines to Drive Growth

AstraZeneca

Elevance Health Inc

Humana

Medtronic

Inflation is easing, says a top thinker for BlackRock, the world's largest asset manager. But it's not falling to what Americans have grown used to.

BlackRock's DeSpirito: Brace For Stubborn Inflation

The FDA approves Sanofi (SNY) and its partner Regeneron's Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis.

Sanofi's (SNY) Dupixent Gets FDA Nod for Prurigo Nodularis

Dupixent ® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis

Press Release: Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis

Availability of the Q3 2022 Memorandum for modelling purposes

News for Sanofi Stock (SNY)